Thermo Fisher Scientific agreed to acquire Clario, a clinical trials software and data management company, in a transaction valued at roughly $8.8–9 billion. The move integrates Clario’s endpoint data capture and analytics into Thermo Fisher’s biopharma services and PPD clinical research capabilities. Company statements framed the deal as expanding digital clinical‑trial capabilities and improving end‑to‑end trial efficiency for sponsors. Analysts note the purchase complements Thermo Fisher’s manufacturing and laboratory services by adding software that streamlines data collection and monitoring. The acquisition reflects consolidation in trial infrastructure as sponsors demand integrated platforms to reduce trial timelines and costs. Regulators and customers will scrutinize integration plans and data governance as the companies merge platforms.